Nokia Corporation Sponsored American Depositary Shares (NOK)

Operating Expenses

€8.31B

TTM · Period ending: · EUR

NOK logo

NOK Operating Expenses

Latest reported€8.31B EUR
NOK TTM Operating Expenses · EUR (€1.11B → €8.31B)
High-resolution chart · PNG

NOK operating expenses history

Trailing twelve months (TTM) · EUR. Each value covers four complete reported quarters.

Nokia Corporation Sponsored American Depositary Shares Operating Expenses — Trailing twelve months (TTM) (EUR)
Period endingOperating Expenses (EUR)
8,309,000,000
8,004,000,000
7,951,000,000
7,884,000,000
7,727,000,000
7,340,000,000
7,274,000,000
6,863,000,000
6,832,000,000
7,007,000,000
6,970,000,000
7,435,000,000
7,739,000,000
7,857,000,000
7,903,000,000
7,393,000,000
7,100,000,000
6,999,000,000
6,678,000,000
6,876,000,000
6,795,000,000
6,935,000,000
7,253,000,000
7,170,000,000
7,262,000,000
7,548,000,000
7,840,000,000
8,140,000,000
8,508,000,000
8,467,000,000
8,504,000,000
8,469,000,000
8,811,000,000
9,011,000,000
9,123,000,000
9,315,000,000
9,078,000,000
9,588,000,000
9,623,000,000
8,307,000,000
7,112,000,000
5,172,000,000
3,840,000,000
3,987,000,000
3,899,000,000
4,058,000,000
4,072,000,000
2,013,000,000
2,114,000,000
2,467,000,000
2,761,000,000
5,768,000,000
7,327,000,000
8,569,000,000
10,677,000,000
12,390,000,000
12,427,000,000
13,164,000,000
12,434,000,000
11,419,000,000
11,365,000,000
10,799,000,000
10,747,000,000
10,836,000,000
11,785,000,000
14,657,000,000
14,915,000,000
15,594,173,810
14,997,173,810
12,299,173,810
12,447,173,810
12,057,188,000
11,732,006,000
10,339,333,000
9,332,256,920
8,390,589,420
7,845,312,900
8,026,923,100
7,894,271,680
7,770,180,180
7,432,967,260
7,573,846,740
7,337,577,240
7,193,257,080
7,127,330,320
6,888,833,320
6,810,984,320
6,967,580,310
6,966,510,060
7,491,012,500
7,191,768,000
6,963,489,320
7,180,059,710
6,673,114,390
6,964,144,990
6,918,417,920
7,472,915,780
7,675,420,180
7,752,207,130
7,488,150,170
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.